<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:32:54Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6676301" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6676301</identifier>
        <datestamp>2019-08-06</datestamp>
        <setSpec>escheart</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">ESC Heart Fail</journal-id>
              <journal-id journal-id-type="iso-abbrev">ESC Heart Fail</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2055-5822</journal-id>
              <journal-id journal-id-type="publisher-id">EHF2</journal-id>
              <journal-title-group>
                <journal-title>ESC Heart Failure</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2055-5822</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6676301</article-id>
              <article-id pub-id-type="pmcid">PMC6676301</article-id>
              <article-id pub-id-type="pmc-uid">6676301</article-id>
              <article-id pub-id-type="pmid">31102328</article-id>
              <article-id pub-id-type="doi">10.1002/ehf2.12448</article-id>
              <article-id pub-id-type="publisher-id">EHF212448</article-id>
              <article-id pub-id-type="other">ESCHF-19-00053</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>High vs. low oxygen therapy in patients with acute heart failure: <styled-content style="fixed-case">HiLo‐HF</styled-content> pilot trial</article-title>
                <alt-title alt-title-type="right-running-head">Oxygen therapy in acute heart failure</alt-title>
                <alt-title alt-title-type="left-running-head">N. Sepehrvand <italic>et al</italic>.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="ehf212448-cr-0001" contrib-type="author">
                  <name>
                    <surname>Sepehrvand</surname>
                    <given-names>Nariman</given-names>
                  </name>
                  <xref ref-type="aff" rid="ehf212448-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="ehf212448-cr-0002" contrib-type="author">
                  <name>
                    <surname>Alemayehu</surname>
                    <given-names>Wendimagegn</given-names>
                  </name>
                  <xref ref-type="aff" rid="ehf212448-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="ehf212448-cr-0003" contrib-type="author">
                  <name>
                    <surname>Rowe</surname>
                    <given-names>Brian H.</given-names>
                  </name>
                  <xref ref-type="aff" rid="ehf212448-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="ehf212448-cr-0004" contrib-type="author">
                  <name>
                    <surname>McAlister</surname>
                    <given-names>Finlay A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="ehf212448-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0004">
                    <sup>4</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="ehf212448-cr-0005" contrib-type="author">
                  <name>
                    <surname>van Diepen</surname>
                    <given-names>Sean</given-names>
                  </name>
                  <xref ref-type="aff" rid="ehf212448-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0006">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib id="ehf212448-cr-0006" contrib-type="author">
                  <name>
                    <surname>Stickland</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <xref ref-type="aff" rid="ehf212448-aff-0008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib id="ehf212448-cr-0007" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Ezekowitz</surname>
                    <given-names>Justin A.</given-names>
                  </name>
                  <address>
                    <email>jae2@ualberta.ca</email>
                  </address>
                  <xref ref-type="aff" rid="ehf212448-aff-0001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="ehf212448-aff-0006">
                    <sup>6</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="ehf212448-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Canadian VIGOUR Centre</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="street">2‐132 Li Ka Shing Centre for Health Research Innovation</named-content>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
                <named-content content-type="post-code">T6G 2E1</named-content>
              </aff>
              <aff id="ehf212448-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Medicine</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="ehf212448-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Emergency Medicine and School of Public Health</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="ehf212448-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Patient Health Outcomes Research and Clinical Effectiveness Unit</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="ehf212448-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <named-content content-type="organisation-division">Division of General Internal Medicine, Department of Medicine</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="ehf212448-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiology, Department of Medicine</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="ehf212448-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <named-content content-type="organisation-division">Department of Critical Care Medicine</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <aff id="ehf212448-aff-0008">
                <label>
                  <sup>8</sup>
                </label>
                <named-content content-type="organisation-division">Division of Pulmonary Medicine, Department of Medicine</named-content>
                <institution>University of Alberta</institution>
                <named-content content-type="city">Edmonton</named-content>
                <named-content content-type="country-part">Alberta</named-content>
                <country country="CA">Canada</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Justin A. Ezekowitz, Canadian VIGOUR Centre, University of Alberta, 2‐132 Li Ka Shing Centre for Health Research Innovation, Edmonton, Alberta, Canada T6G 2E1. Email: <email>jae2@ualberta.ca</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>17</day>
                <month>5</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2019</year>
              </pub-date>
              <volume>6</volume>
              <issue>4</issue>
              <issue-id pub-id-type="doi">10.1002/ehf2.v6.4</issue-id>
              <fpage>667</fpage>
              <lpage>677</lpage>
              <history>
                <date date-type="received">
                  <day>14</day>
                  <month>3</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>4</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2019 The Heart Failure Association of the European Society of Cardiology / John Wiley & Sons Ltd <copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2019 The Authors. ESC Heart Failure published by John Wiley &amp; Sons Ltd on behalf of the European Society of Cardiology.</copyright-statement>
                <license license-type="creativeCommonsBy-nc">
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EHF2-6-667.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="ehf212448-sec-0001">
                  <title>Aims</title>
                  <p>Most patients with acute heart failure (AHF) are treated with supplemental oxygen during hospitalization. In this study, we investigated the effect of oxygen titrated to high vs. low pulse oximetry targets in patients hospitalized with AHF.</p>
                </sec>
                <sec id="ehf212448-sec-0002">
                  <title>Methods and results</title>
                  <p>In a pilot, open‐label randomized controlled trial (RCT), 50 patients who were admitted with AHF were randomized to either high (≥96%) or low (90–92%) SpO<sub>2</sub> targets. Oxygen was manually titrated to the assigned target ranges for 72 h. The primary endpoint was the change in N‐terminal pro‐brain‐type natriuretic peptide (NT‐proBNP) from randomization to 72 h, and secondary endpoints included patient‐reported dyspnoea by visual analogue scale (VAS), patient global assessment (PGA), peak expiratory flow (PEF) within 72 h, and clinical outcomes up to 30 days following hospital discharge. The median age was 73.5 years, and 42% were women. The change in NT‐proBNP was −6963 (−13 345, −1253) pg/mL in the high SpO<sub>2</sub> group and −2093 (−5692, −353) pg/mL in the low SpO<sub>2</sub> group (<italic>P</italic> = 0.46), and the 72 h to baseline NT‐proBNP ratio was similar between groups (0.7 vs. 0.6, <italic>P</italic> = 0.51). There were no differences between arms in change in dyspnoea VAS (<italic>P</italic> = 0.86), PGA (<italic>P</italic> = 0.91), PEF (<italic>P</italic> = 0.52), in‐hospital mortality (4.0% vs. 8.0%, <italic>P</italic> = 0.50), or 30 day heart failure readmission rates (20.8% vs. 8.7%, <italic>P</italic> = 0.22).</p>
                </sec>
                <sec id="ehf212448-sec-0003">
                  <title>Conclusions</title>
                  <p>In this study, no differences were observed in the primary or secondary outcomes for patients randomized to high vs. low SpO<sub>2</sub> targets. Further RCTs with larger sample sizes are warranted to determine the efficacy and safety of oxygen therapy in patients with AHF.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="ehf212448-kwd-0001">Supplemental oxygen</kwd>
                <kwd id="ehf212448-kwd-0002">Heart failure</kwd>
                <kwd id="ehf212448-kwd-0003">Randomized controlled trial</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>Government of Canada</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Canadian Institutes of Health Research</funding-source>
                </award-group>
                <award-group>
                  <funding-source>University of Alberta</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Alberta Innovates ‐ Health Solutions</funding-source>
                </award-group>
                <award-group>
                  <funding-source>Heart and Stroke Foundation of Canada</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="3"/>
                <page-count count="11"/>
                <word-count count="4281"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>component-id</meta-name>
                  <meta-value>ehf212448</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>August 2019</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.7 mode:remove_FC converted:02.08.2019</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="ehf212448-cit-0000"><string-name><surname>Sepehrvand</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Alemayehu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Rowe</surname>, <given-names>B. H.</given-names></string-name>, <string-name><surname>McAlister</surname>, <given-names>F. A.</given-names></string-name>, <string-name><surname>van Diepen</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Stickland</surname>, <given-names>M.</given-names></string-name>, and <string-name><surname>Ezekowitz</surname>, <given-names>J. A.</given-names></string-name> (<year>2019</year>) <article-title>High vs. low oxygen therapy in patients with acute heart failure: <styled-content style="fixed-case">HiLo‐HF</styled-content> pilot trial</article-title>. <source xml:lang="en">ESC Heart Failure</source>, <volume>6</volume>: <fpage>667</fpage>–<lpage>677</lpage>. <pub-id pub-id-type="doi">10.1002/ehf2.12448</pub-id>.</mixed-citation>
              </p>
            </notes>
          </front>
          <body>
            <sec id="ehf212448-sec-0004">
              <title>Introduction</title>
              <p>Supplemental oxygen (O<sub>2</sub>) therapy is a routine treatment in the management of many patients with dyspnoea, including those with acute heart failure (AHF).<xref rid="ehf212448-bib-0001" ref-type="ref">1</xref> Regardless of the arterial O<sub>2</sub> saturation levels, O<sub>2</sub> is often administered in these patients on the basis of the clinicians' or patients' belief that it will ameliorate dyspnoea, or that improving oxygenation of the myocardial tissue will improve cardiac function.<xref rid="ehf212448-bib-0002" ref-type="ref">2</xref>, <xref rid="ehf212448-bib-0003" ref-type="ref">3</xref> However, given the lack of high‐quality evidence, there is an ongoing debate regarding the role that O<sub>2</sub> plays in the treatment of patients with AHF.</p>
              <p>While there is consensus among clinicians regarding the treatment of hypoxaemia (low O<sub>2</sub> saturation levels or SpO<sub>2</sub>) in the acute setting, it is unclear whether O<sub>2</sub> should be administered in AHF patients who have normal O<sub>2</sub> saturation. Several physiologic studies have suggested deleterious effects of hyperoxia (i.e. high O<sub>2</sub>) on cardiac function.<xref rid="ehf212448-bib-0004" ref-type="ref">4</xref>, <xref rid="ehf212448-bib-0005" ref-type="ref">5</xref>, <xref rid="ehf212448-bib-0006" ref-type="ref">6</xref>, <xref rid="ehf212448-bib-0007" ref-type="ref">7</xref> These effects are thought to be due to high O<sub>2</sub> stimulating the overproduction of reactive O<sub>2</sub> species, and hyperoxia‐induced vasoconstriction that can lead to decreased coronary blood flow, and eventually to cardiac dysfunction.<xref rid="ehf212448-bib-0003" ref-type="ref">3</xref> Previous studies have shown that the patients' perception of dyspnoea is not directly correlated with SpO<sub>2</sub>.<xref rid="ehf212448-bib-0002" ref-type="ref">2</xref>
</p>
              <p>Several major randomized controlled trials (RCTs) have shown O<sub>2</sub> therapy to have no clinical benefits in patients without hypoxaemia presenting with acute myocardial infarction,<xref rid="ehf212448-bib-0008" ref-type="ref">8</xref>, <xref rid="ehf212448-bib-0009" ref-type="ref">9</xref> and others suggested possible harms.<xref rid="ehf212448-bib-0010" ref-type="ref">10</xref> Recent heart failure (HF) guidelines have taken a cautious, yet variable, approach regarding recommendations on the use of supplemental O<sub>2</sub> therapy in normoxaemic patients with AHF.<xref rid="ehf212448-bib-0011" ref-type="ref">11</xref>, <xref rid="ehf212448-bib-0012" ref-type="ref">12</xref>, <xref rid="ehf212448-bib-0013" ref-type="ref">13</xref>
</p>
              <p>We designed the High vs. Low SpO<sub>2</sub> oxygen therapy in patients with acute Heart Failure (<styled-content style="fixed-case">HiLo‐HF</styled-content>) pilot trial to investigate the feasibility of conducting an RCT as well as to explore the effects of supplemental O<sub>2</sub> therapy in patients who were hospitalized with AHF.</p>
            </sec>
            <sec id="ehf212448-sec-0005">
              <title>Methods</title>
              <p><styled-content style="fixed-case">HiLo‐HF</styled-content> trial was a single‐centre, pilot, open‐label RCT designed to test the feasibility, efficacy, and safety of targeting a high (high SpO<sub>2</sub>) vs. low (low SpO<sub>2</sub>) O<sub>2</sub> saturation range. The study was approved by the Health Research Ethics Board of the University of Alberta, and written informed consent was obtained from all subjects prior to study participation. The Canadian VIGOUR Centre (thecvc.ca) managed the trial. The trial was registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT03110042).</p>
              <sec id="ehf212448-sec-0006">
                <title>Participants</title>
                <p>Patients who presented to the emergency department (ED) at University of Alberta Hospital with AHF were screened for this study. The inclusion and exclusion criteria of the <styled-content style="fixed-case">HiLo‐HF</styled-content> pilot RCT were as follows.</p>
                <sec id="ehf212448-sec-0007">
                  <title>Inclusion criteria</title>
                  <p>Patients who met the inclusion criteria were &gt;40 years of age presenting to the ED with objective AHF (BNP &gt; 400 pg/mL and/or chest X‐ray with pulmonary congestion) and with a planned admission for the treatment of HF as the primary diagnosis. Patients were eligible for randomization within 16 h of presenting to the ED.</p>
                </sec>
                <sec id="ehf212448-sec-0008">
                  <title>Exclusion criteria</title>
                  <p>Patients on home O<sub>2</sub>, known prior hypercapnic failure (PaCO<sub>2</sub> &gt; 50 mmHg), asthma, primary pulmonary hypertension, requiring urgent positive pressure ventilation or intubation, or on &gt;10 L/min O<sub>2</sub> were excluded.</p>
                  <p>Patients who did not meet the inclusion criteria for the <styled-content style="fixed-case">HiLo‐HF</styled-content> trial were potentially eligible for the <styled-content style="fixed-case">HiLo‐HF</styled-content> registry (eligibility criteria for <styled-content style="fixed-case">HiLo‐HF</styled-content> registry provided in <italic>Table</italic>
<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material">S1</xref>). The pilot RCT included 50 patients (25 patients in each arm) as a demonstration of feasibility (<italic>Figure</italic>
<xref rid="ehf212448-fig-0001" ref-type="fig">1</xref>).</p>
                  <fig fig-type="Figure" xml:lang="en" id="ehf212448-fig-0001" orientation="portrait" position="float">
                    <label>Figure 1</label>
                    <caption>
                      <p>Patient flow diagram. Note: O<sub>2</sub>, oxygen; pts, patients; SpO<sub>2</sub>, peripheral oxygen saturation level.</p>
                    </caption>
                    <graphic id="nlm-graphic-1" xlink:href="EHF2-6-667-g001"/>
                  </fig>
                </sec>
              </sec>
              <sec id="ehf212448-sec-0009">
                <title>Intervention</title>
                <p>Patients were randomized in the ED to either high SpO<sub>2</sub> or low SpO<sub>2</sub> groups after providing informed written consent (<italic>Figure</italic>
<xref rid="ehf212448-fig-0002" ref-type="fig">2</xref>). All patients had nasal cannula placed as the usual standard of care, and patients were titrated to the pre‐specified target ranges according to the detailed instructions provided in the <xref rid="ehf212448-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.
<list list-type="order" id="ehf212448-list-0001"><list-item id="ehf212448-li-0001"><p>High SpO<sub>2</sub> group: In the high SpO<sub>2</sub> arm, patients were manually titrated by a trained research co‐ordinator to a target SpO<sub>2</sub> range of ≥96%.</p></list-item><list-item id="ehf212448-li-0002"><p>Low SpO<sub>2</sub> group: In the low SpO<sub>2</sub> arm, patients were manually titrated by a trained research co‐ordinator to the target SpO<sub>2</sub> range of 90–92%.</p></list-item></list>
</p>
                <fig fig-type="Figure" xml:lang="en" id="ehf212448-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <p>Study groups and primary/secondary endpoints. Note: HF, heart failure; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; PEF, peak expiratory flow; PGA, patient global assessment; R, randomization; SpO<sub>2</sub>, peripheral oxygen saturation level; VAS, visual analogue scale.</p>
                  </caption>
                  <graphic id="nlm-graphic-3" xlink:href="EHF2-6-667-g002"/>
                </fig>
                <p>Consented patients were randomly allocated to study groups via the automated web‐based system within REDCap.<xref rid="ehf212448-bib-0014" ref-type="ref">14</xref> The allocation was concealed. Time at randomization was considered as study time zero (T0). All patients received usual standard of care with the exception of their O<sub>2</sub> management. After 72 h, patients were switched over to usual care for O<sub>2</sub> therapy at the discretion of the treating physician. We selected the 72 h time frame because in previous studies most patients with AHF were no longer on O<sub>2</sub> by 72 h.<xref rid="ehf212448-bib-0002" ref-type="ref">2</xref>
</p>
              </sec>
              <sec id="ehf212448-sec-0010">
                <title>Follow‐up</title>
                <p>Patients were assessed on a daily basis while in hospital and on day of discharge to assess for in‐hospital safety events [clinically assessed worsening HF (WHF), or other clinical events]. Patients were followed up by telephone and health records review for a period of 30 days after hospital discharge.</p>
              </sec>
              <sec id="ehf212448-sec-0011">
                <title>Endpoints</title>
                <p>The primary endpoint of this study was the change in N‐terminal pro‐brain‐type natriuretic peptide (NT‐proBNP) from baseline to 72 h (expressed as an absolute change and as a ratio of the baseline value).<xref rid="ehf212448-bib-0015" ref-type="ref">15</xref> Secondary endpoints included (i) change in dyspnoea on visual analogue scale (VAS) from baseline to 72 h [area under the curve (AUC), mm/h]<xref rid="ehf212448-bib-0016" ref-type="ref">16</xref>, <xref rid="ehf212448-bib-0017" ref-type="ref">17</xref>; (ii) change in global symptoms using patient global assessment (PGA) measure to 72 h (AUC, mm/h)<xref rid="ehf212448-bib-0018" ref-type="ref">18</xref>; (iii) change in peak expiratory flow (PEF) at 72 h (L/min)<xref rid="ehf212448-bib-0002" ref-type="ref">2</xref>; (iv) WHF at 7 days; (v) diuretic response as defined by weight loss up to 72 h per 40 mg of furosemide or equivalent<xref rid="ehf212448-bib-0019" ref-type="ref">19</xref>; and (vi) clinical event at 30 days following hospital discharge (all‐cause mortality and HF readmission).</p>
                <p>Worsening HF was defined as signs and/or symptoms of HF that require intensification of intravenous therapy for HF, or new institution of mechanical ventilator support (continuous positive airway pressure (CPAP), non‐invasive ventilation (NIV), or intubation) or circulatory support (mechanical circulatory assist devices).<xref rid="ehf212448-bib-0016" ref-type="ref">16</xref>, <xref rid="ehf212448-bib-0017" ref-type="ref">17</xref>
</p>
                <p>Directly measured patient‐reported outcomes (e.g. dyspnoea VAS and PGA) were collected at set time points as per <italic>Figure</italic>
<xref rid="ehf212448-fig-0002" ref-type="fig">2</xref>. For dyspnoea VAS, patients were asked to evaluate their breathing by marking a 10 cm vertical line, with the top labelled ‘best you have ever had’ and the bottom labelled ‘worst you have ever had’. We scored the patients' markings on a scale of 0 to 100 by measuring the distance in millimetres from the bottom of the line. A similar approach was used for PGA to evaluate patients' general well‐being. Given the open‐label design, a research co‐ordinator who was blinded to the patient's group allocation was assigned to perform or record the subjective endpoints evaluations (i.e. dyspnoea VAS and PGA). Samples for NT‐proBNP were collected via standardized laboratory procedures, processed, and frozen for batch analysis at the end of the trial. The Roche NT‐proBNP assays were performed by the University of Alberta Clinical Trials laboratory on the Elecsys 2010 (Roche Diagnostics, Manheim, Germany; reporting range 5 to 35 000 pg/mL).</p>
              </sec>
              <sec id="ehf212448-sec-0012">
                <title>Statistical analysis</title>
                <p>All analyses were performed on the basis of intention‐to‐treat principle. Categorical variables were summarized as frequency and percentages and compared between groups using the Pearson <italic>χ</italic>
<sup>2</sup> test or Fisher's exact test, as appropriate. Continuous variables were summarized as median with inter‐quartile range (IQR) and compared using the Mann–Whitney test. No data imputation has been performed when data are missing in one or more data points. Analysis of covariance (ANCOVA) was applied for the primary endpoint analysis. Given the non‐normal distribution, the values were log transformed prior to ANCOVA. Summary results were reported in the original scale, while the significance test result was that of the changes in log scale applying Wald statistic.</p>
                <p>The AUC representing the change in VAS, PGA, and PEF from baseline to 72 h was computed according to the trapezoidal rule for each patient<xref rid="ehf212448-bib-0018" ref-type="ref">18</xref> and was compared between the study arms using ANCOVA. Similarly, ANCOVA was applied to compare the relative changes of dyspnoea VAS AUC, PGA, and PEF from baseline to 72 h. The 30 day clinical events were estimated using the Kaplan–Meier method and were compared between the intervention arms using the log‐rank test. Patients who remained alive and without hospital readmission were censored at their last available study date. All statistical analyses were conducted using SAS statistical software (version 9.4; SAS Institute, Cary, North Carolina).</p>
              </sec>
            </sec>
            <sec id="ehf212448-sec-0013">
              <title>Results</title>
              <p>Two‐hundred thirty‐three patients who presented to ED with AHF were screened for eligibility between 24 November 2016 and 27 February 2018, and 50 patients were enrolled into the <styled-content style="fixed-case">HiLo‐HF</styled-content> pilot trial (25 per arm). Patients excluded are presented in <italic>Figure</italic>
<xref rid="ehf212448-fig-0001" ref-type="fig">1</xref>.</p>
              <p>The patients enrolled in the trial had a median age of 73.5 years, 42% were women, 70% had prior history of HF, 56% had coronary artery disease (CAD), 18% had chronic obstructive pulmonary disease (COPD), and 62% were current/past smokers (<italic>Table</italic>
<xref rid="ehf212448-tbl-0001" ref-type="table">1</xref>). There were no clinically important differences in demographic or clinical features between arms.</p>
              <table-wrap id="ehf212448-tbl-0001" xml:lang="en" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline centeracteristics of the patients in <styled-content style="fixed-case">HiLo‐HF</styled-content> trial and registry</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col align="left" span="1"/>
                  <col align="center" span="1"/>
                  <col align="center" span="1"/>
                  <col align="center" span="1"/>
                  <col align="center" span="1"/>
                  <col align="center" span="1"/>
                  <thead valign="bottom">
                    <tr style="border-bottom:solid 1px #000000">
                      <th rowspan="2" style="border-bottom:solid 1px #000000" align="center" valign="bottom" colspan="1"/>
                      <th rowspan="2" align="center" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">HiLo registry (<styled-content style="italic-in-any-context">n</styled-content> = 60)</th>
                      <th colspan="4" align="center" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">HiLo pilot RCT</th>
                    </tr>
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="center" valign="bottom" rowspan="1" colspan="1">All (<styled-content style="italic-in-any-context">n</styled-content> = 50)</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">High SpO<sub>2</sub> target (<styled-content style="italic-in-any-context">n</styled-content> = 25)</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1">Low SpO<sub>2</sub> target (<styled-content style="italic-in-any-context">n</styled-content> = 25)</th>
                      <th align="center" valign="bottom" rowspan="1" colspan="1"><styled-content style="italic-in-any-context">P</styled-content>‐value</th>
                    </tr>
                  </thead>
                  <tbody valign="top">
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Age, year</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">77 (65.5, 86)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">73.5 (67, 84)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">73.0 (70, 77)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">74 (59, 86)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.75</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Women, <italic>n</italic> (%)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">21 (35)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">21 (42)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (40)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.77</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Race</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Aboriginal</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.14</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Caucasian</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">49 (81.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">39 (78)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">20 (80)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">19 (76)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.73</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (16.6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.27</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Medical history</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Heart failure</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">34 (56.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">35 (70)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (60)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">20 (80)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.12</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Ischaemic</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">21 (35)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">22 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (36)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (52)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.25</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Non‐ischaemic</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (21.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (26)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (24)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7 (28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">AF/flutter</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">35 (58.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">26 (52)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12 (48)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.57</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cardiac devices<xref ref-type="fn" rid="ehf212448-note-0002">a</xref>
</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (18.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">CAD</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">26 (43.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">28 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">MI</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (42.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (50)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (57.1)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (42.9)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.45</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">PCI</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (42.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (35.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (42.9)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.43</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">CABG</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (42.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (32.1)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (35.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.68</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Prior stroke</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">15 (25)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (20.4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (25)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (16)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.43</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diabetes</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">21 (35)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">22 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (32)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.08</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">HTN</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">45(75)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">35 (70)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">16 (64)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">19 (76)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.35</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">COPD</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">19 (31.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (18)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (24)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (12)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.27</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asthma</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (3.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">n/a</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Smoking</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">36 (60)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">31 (62)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">18 (72)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (52)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.14</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Current</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (11.1)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (29)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (33.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (23.1)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.53</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Pack/year</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">20 (7.3, 38.8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">27.5 (10, 40)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">33.8 (12.5, 45)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">25.0 (6.3, 31)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.14</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Cancer within past 5 years</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (18.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1.00</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Charlson Index</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (3.5, 6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (3, 6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (3, 5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (4, 6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.10</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline LVEF, <italic>n</italic> (%)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.33</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≤20%</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">8 (13.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4 (8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (12)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">21–40%</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12 (20)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">20 (40)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (36)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">41–45%</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7 (11.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (12)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">46–50%</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (10)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">3 (12)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">≥51%</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">24 (40)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">16 (32)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9 (36)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7 (28)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Missing</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (10)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Mode of ED arrival, <italic>n</italic> (%)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.59</td>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Direct admission from clinic</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (1.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (2)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">1 (4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Self‐presentation</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">30 (50)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">27 (54)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14 (56)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13 (52)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">EMS</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">29 (48.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">22 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">O<sub>2</sub> in EMS, <italic>n</italic> (%)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">16 (55.2)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12 (54.5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7 (63.6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5 (45.5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.39</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">O<sub>2</sub> in EMS, L/min</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2.0 (2, 4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5.5 (3, 7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">5.5 (4, 8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4.0 (2, 6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.61</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pre‐randomization SpO<sub>2</sub>, %</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">95 (93, 97)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">94.5 (93, 97)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">94 (92, 96)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">96 (93, 98)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.12</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pre‐randomization O<sub>2</sub>, <italic>n</italic> (%)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">26 (43.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">21 (42)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11 (44)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">10 (40)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.77</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pre‐randomization O<sub>2</sub>, L/min</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (2, 3.2)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (2, 3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2 (2, 3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">2.2 (2, 4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.37</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Time</td>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">From triage to admission order, h</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11.2 (8, 13.8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7.2 (5, 11.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7.5 (4.7, 11.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">7.0 (5.1, 10.6)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.67</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">From triage to enrolment, h</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">19.2 (7.2, 21.5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11.4 (7.3, 13.5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11.4 (6.2, 13.5)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">11.3 (8.1, 14.2)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.47</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">From triage to first NT‐proBNP test, h</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">—</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13.2 (8.0, 15.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13.1 (7.5, 15.4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">13.2 (8.2, 15.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.44</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">From triage to disposition from ED, h</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">16.2 (11.3, 21.8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12.8 (9, 15.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">12.7 (6.6, 15.3)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">14.6 (9.4, 16.8)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.24</td>
                    </tr>
                    <tr>
                      <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">From triage to discharge from hospital, days</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6 (2.8, 12.4)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">6.3 (3.7, 11)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">4.7 (2.7, 6.7)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">9.5 (4.9, 19.9)</td>
                      <td align="center" valign="top" rowspan="1" colspan="1">0.01</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="ehf212448-note-0001">
                    <p>Note: AF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ED, emergency department; EMS, emergency medical services; HiLo, high‐dose oxygen/low‐dose oxygen; HTN, hypertension; MI, myocardial infarction; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; O<sub>2</sub>, oxygen; PCI, percutaneous coronary intervention; SpO<sub>2</sub>, peripheral oxygen saturation level.</p>
                  </fn>
                  <fn id="ehf212448-note-0002">
                    <label>a</label>
                    <p>Cardiac devices including pacemaker, implantable cardioverter defibrillator, and cardiac resynchronization therapy. Unless described otherwise, median (25th percentile, 75th percentile) are reported.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Twenty‐two (44%) patients presented via ambulance, and the median rate of administered O<sub>2</sub> in the ambulance was 5.5 L/min among the 12 who received O<sub>2</sub> before the ED.</p>
              <p>Pre‐randomization SpO<sub>2</sub> was 94% (IQR 92, 96) and 96% (IQR 93, 98), respectively, in the high and low SpO<sub>2</sub> groups with 11 (44%) and 10 (40%) patients receiving O<sub>2</sub> (median 2 L/min O<sub>2</sub>; IQR 2, 3).</p>
              <p>The median time from triage to disposition from ED was 12.8 (IQR 9.0, 15.7) h, which was not different between study arms (<italic>P</italic> = 0.24).</p>
              <sec id="ehf212448-sec-0014">
                <title>Adherence to study protocol</title>
                <p>At individual assessment time points, 83–94% of patients in the high SpO<sub>2</sub> group and 5–30% of patients in the low SpO<sub>2</sub> group were at the assigned SpO<sub>2</sub> ranges. However, when we accounted for supplemental O<sub>2</sub> volumes, only 14.5%, 18.7%, 6.9%, and 10.2% had non‐adherence to the study protocol (defined as SpO<sub>2</sub> levels out of the target range ±1% with inappropriate O<sub>2</sub> volumes administered) at 6, 24, 48, and 72 h after randomization, respectively. The rate of non‐adherence was not significantly different between study groups (<italic>Table</italic>
<xref rid="ehf212448-tbl-0002" ref-type="table">2</xref> and <italic>Figure</italic>
<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material">S1</xref>).</p>
                <table-wrap id="ehf212448-tbl-0002" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Adherence to study protocol in <styled-content style="fixed-case">HiLo‐HF</styled-content> pilot randomized controlled trial</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">All (<styled-content style="italic-in-any-context">n</styled-content> = 50)</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">High SpO<sub>2</sub> target (<styled-content style="italic-in-any-context">n</styled-content> = 25)</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Low SpO<sub>2</sub> target (<styled-content style="italic-in-any-context">n</styled-content> = 25)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td colspan="4" align="left" valign="top" rowspan="1">% on determined SpO<sub>2</sub> range ±1%, <italic>n</italic> (%)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">27 (56.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20 (83.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (29.2)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">24 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25 (53.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20 (87)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (20.8)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">48 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">25 (58.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18 (85.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7 (31.8)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18 (46.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17 (94.4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1 (4.8)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">% on O<sub>2</sub>, <italic>n</italic> (%)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">27 (56.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18 (75)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9 (37.5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">24 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18 (38.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (52.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6 (25)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">48 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">17 (39.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">13 (61.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (18.2)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16 (41)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">12 (66.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4 (19)</td>
                      </tr>
                      <tr>
                        <td colspan="4" align="left" valign="top" rowspan="1">O<sub>2</sub> volume in pts treated with O<sub>2</sub>, L/min</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (2, 3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.5 (2, 4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (2, 3)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">24 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.5 (2, 4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3 (2, 4)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (1.3, 2.6)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">48 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (2, 3.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.5 (2, 4.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2 (1.2, 3.1)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.2 (1.1, 3.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2.5 (1.6, 6.1)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1.7 (1, 3.2)</td>
                      </tr>
                      <tr>
                        <td colspan="4" align="left" valign="top" rowspan="1">Number of pts with SpO<sub>2</sub> out of target range ±1% with inappropriate O<sub>2</sub> volume, <italic>n</italic> (%)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">6 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7/48 (14.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3/24 (12.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4/24 (16.6)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">24 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">9/48 (18.7)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3/24 (12.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6/24 (25)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">48 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3/43 (6.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">2/21 (9.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1/22 (4.5)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4/39 (10.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">1/18 (5.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">3/21 (14.2)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="ehf212448-note-0003">
                      <p>Note: HiLo, high‐dose oxygen/low‐dose oxygen; O<sub>2</sub>, oxygen; pts, patients; SpO<sub>2</sub>, peripheral oxygen saturation level.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="ehf212448-sec-0015">
                <title>Primary endpoint</title>
                <p>Follow‐up (i.e. 72 h) NT‐proBNP tests were missed in 14 patients: seven patients were discharged before 72 h, one patient left against medical advice, one patient refused further blood tests, one was withdrawn from the study for safety reasons, and four were missed because of staff error. Hence, the analysis for primary endpoint was limited to the remaining 36 patients with available baseline and follow‐up NT‐proBNP results.</p>
                <p>Baseline and 72 h NT‐proBNP levels were not statistically significantly different between groups with high and low SpO<sub>2</sub> targets [<italic>Table</italic>
<xref rid="ehf212448-tbl-0003" ref-type="table">3</xref> and <italic>Figure</italic>
<xref rid="ehf212448-fig-0003" ref-type="fig">3</xref>(A)]. Although numerically higher in the high SpO<sub>2</sub> arm, NT‐proBNP change was not significantly different between study arms. Ratio change of NT‐proBNP to 72 h was also similar between trial arms (<italic>P</italic> = 0.51). Moreover, there was no difference between groups in terms of change in NT‐proBNP after adjustment for age, sex, past history of diabetes mellitus (DM), chronic kidney disease (CKD), COPD, cerebrovascular accident (CVA), and prior HF (<italic>P</italic> = 0.74).</p>
                <table-wrap id="ehf212448-tbl-0003" xml:lang="en" orientation="portrait" position="float">
                  <label>Table 3</label>
                  <caption>
                    <p>Primary and secondary endpoints</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th rowspan="2" align="left" valign="top" colspan="1"/>
                        <th rowspan="2" align="center" valign="top" colspan="1"><styled-content style="fixed-case">HiLo‐HF</styled-content> registry</th>
                        <th colspan="4" align="center" valign="top" rowspan="1"><styled-content style="fixed-case">HiLo‐HF</styled-content> pilot RCT</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 36)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">High SpO<sub>2</sub> target (<italic>n</italic> = 18)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Low SpO<sub>2</sub> target (<italic>n</italic> = 18)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">NT‐proBNP</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Baseline, pg/mL</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">—</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">14 140.1 (5570.6, 27 806.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 987.9 (6025.6, 29 785.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 262.5 (4355.3, 27 223.0)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.45<xref ref-type="fn" rid="ehf212448-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h, pg/mL</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">—</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">7108.9 (4310.5, 17 007.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">6479.7 (4529.5, 12 304.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 156.8 (4001.8, 17 133.8)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.72<xref ref-type="fn" rid="ehf212448-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ΔNT‐proBNP, pg/mL</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">—</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−3971.4 (−11 194.5, −1049.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−6963.5 (−13 345.1, −1 253.3)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">−2093.1 (−5692.1, −353.5)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.46<xref ref-type="fn" rid="ehf212448-note-0005">a</xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h to baseline ratio</td>
                        <td align="center" valign="top" rowspan="1" colspan="1">—</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.5, 0.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.7 (0.3, 0.8)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.6 (0.5, 0.9)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">0.51<xref ref-type="fn" rid="ehf212448-note-0006">b</xref>
</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="(" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="top">
                      <tr style="border-bottom:solid 1px #000000">
                        <th colspan="6" align="center" valign="top" rowspan="1">Secondary endpoints</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="top" rowspan="1" colspan="1"/>
                        <th align="center" valign="top" rowspan="1" colspan="1"><styled-content style="fixed-case">HiLo‐HF</styled-content> registry (<italic>n</italic> = 43)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">All (<italic>n</italic> = 39)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">High SpO<sub>2</sub> target (<italic>n</italic> = 18)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1">Low SpO<sub>2</sub> target (<italic>n</italic> = 21)</th>
                        <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">VAS</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ΔVAS, mm</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 (5, 35)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (5, 25)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (5, 25)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (7, 20)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.86<xref ref-type="fn" rid="ehf212448-note-0006">b</xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">VAS AUC, mm·h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5295 (4537, 5983)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5160 (4380, 5932)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5160 (4050, 6150)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5167 (4552, 5703)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.73</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">PGA</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ΔPGA, mm</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">20 (10, 30)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (0, 20)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">5 (0, 20)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">10 (0, 15)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.91<xref ref-type="fn" rid="ehf212448-note-0006">b</xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PGA AUC, mm·h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4320 (3360, 5280)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4620 (3840, 5760)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4860 (4290, 5775)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">4320 (3795, 5670)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.63</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">PEF</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ΔPEF, L/min</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">45 (0–80)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">47.5 (20, 75)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">52.5 (20, 90)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">42.5 (25, 67.5)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.52<xref ref-type="fn" rid="ehf212448-note-0006">b</xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PEF AUC, L/min·h</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">19 920 (12 795, 24 840)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">16 740 (14 610, 22 110)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">15 660 (12 540, 19 500)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">18 960 (16 080, 24 840)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.19</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Diuretic response</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">72 h/baseline weight ratio</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.96 (0.94, 0.98)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.96 (0.94, 0.98)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.97 (0.94, 0.98)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.96 (0.93, 0.97)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.55</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="ehf212448-note-0004">
                      <p>Note: AUC, area under the curve; HiLo, high‐dose oxygen/low‐dose oxygen; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; PEF, peak expiratory flow; PGA, patient global assessment; RCT, randomized controlled trial; VAS, visual analogue scale.</p>
                    </fn>
                    <fn id="ehf212448-note-0005">
                      <label>a</label>
                      <p><italic>P</italic>‐value based on comparison of high and low SpO<sub>2</sub> groups on logarithmic scale.</p>
                    </fn>
                    <fn id="ehf212448-note-0006">
                      <label>b</label>
                      <p>Test of difference at 72 h adjusting for baseline applying the analysis of covariance model. Unless described otherwise, median (25th percentile, 75th percentile) are reported.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig fig-type="Figure" xml:lang="en" id="ehf212448-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Change in NT‐proBNP levels (A), dyspnoea VAS (B), patient global assessment (C), and peak expiratory flow (D) from baseline to 72 h in groups with high and low SpO<sub>2</sub> targets. Note: AUC, area under the curve; BL, baseline; NT‐proBNP, N‐terminal pro‐brain‐type natriuretic peptide; PEF, peak expiratory flow; PGA, patient global assessment; SpO<sub>2</sub>, peripheral oxygen saturation level; VAS, visual analogue scale.</p>
                  </caption>
                  <graphic id="nlm-graphic-5" xlink:href="EHF2-6-667-g003"/>
                </fig>
              </sec>
              <sec id="ehf212448-sec-0016">
                <title>Secondary endpoints</title>
                <sec id="ehf212448-sec-0017">
                  <title>Dyspnoea scores</title>
                  <p>The dyspnoea VAS was not different between study arms in different study time points from 6 to 72 h after randomization (all <italic>P</italic> &gt; 0.05) (<italic>Table</italic>
<xref rid="ehf212448-tbl-0003" ref-type="table">3</xref>). The change in dyspnoea from baseline to 72 h was not different between study groups, and VAS AUC was similar between groups with high and low SpO<sub>2</sub> set points [<italic>Figure</italic>
<xref rid="ehf212448-fig-0003" ref-type="fig">3</xref>(B)].</p>
                </sec>
                <sec id="ehf212448-sec-0018">
                  <title>Patient global assessment</title>
                  <p>Similarly, the patient symptoms according to PGA were not different between study arms in different study time points from 6 to 72 h after randomization (all <italic>P</italic> &gt; 0.05). The change in PGA from baseline to 72 h was not different between study groups, and PGA AUC was similar between two arms of the trial [<italic>Table</italic>
<xref rid="ehf212448-tbl-0003" ref-type="table">3</xref> and <italic>Figure</italic>
<xref rid="ehf212448-fig-0003" ref-type="fig">3</xref>(C)].</p>
                </sec>
                <sec id="ehf212448-sec-0019">
                  <title>Peak expiratory flow</title>
                  <p>The PEF was not significantly different between study groups in different time points [<italic>Figure</italic>
<xref rid="ehf212448-fig-0003" ref-type="fig">3</xref>(D)]. In ANCOVA, adjusting for baseline values, the change in PEF from baseline to 72 h (<italic>P</italic> = 0.52) and PEF AUC (<italic>P</italic> = 0.19) was not different between two study arms.</p>
                </sec>
                <sec id="ehf212448-sec-0020">
                  <title>Diuretic response</title>
                  <p>Data for both the baseline and 72 h weight were only available for 39 patients. Follow‐up/baseline weight ratio was similar between study groups [median (IQR) 0.97 (0.94, 0.98) vs. 0.96 (0.93, 0.97) in the high vs. low SpO<sub>2</sub> arm, respectively; <italic>P</italic> = 0.55].</p>
                </sec>
                <sec id="ehf212448-sec-0021">
                  <title>Worsening heart failure</title>
                  <p>Worsening HF occurred in one patient (4%) from the low SpO<sub>2</sub> group, and there was no difference between study arms in terms of WHF (<italic>P</italic> = 1.0).</p>
                </sec>
                <sec id="ehf212448-sec-0022">
                  <title>Clinical outcomes</title>
                  <p>For 30 day clinical events, no missing patient values occurred following health records surveillance, so the analysis included all 50 patients. One patient in the high SpO<sub>2</sub> arm and two patients in the low SpO<sub>2</sub> arm died in hospital (4.0% vs. 8.0%, <italic>P</italic> = 0.50). Among those who survived to be discharged, five patients in the high SpO<sub>2</sub> arm and two patients in the low SpO<sub>2</sub> arm were re‐hospitalized within 30 days after hospital discharge (20.8% vs. 8.7%, <italic>P</italic> = 0.22). The Kaplan–Meier curve showed no difference between study groups in death/re‐hospitalization at 30 days following hospital discharge (<italic>P</italic>‐value for log‐rank test = 0.36) (<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material"><italic>Figure</italic> S3</xref>).</p>
                </sec>
                <sec id="ehf212448-sec-0023">
                  <title>Length of stay</title>
                  <p>The median length of hospital stay (LOS) was 6.3 (IQR 3.7, 11.0) days in the pilot RCT, and it was significantly longer in the low SpO<sub>2</sub> group than in the high SpO<sub>2</sub> group (9.5 vs. 4.7 days, <italic>P</italic> = 0.011) (<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material"><italic>Figure</italic> S2</xref>). However, after adjustment for age, sex, residence type (home vs. long‐term care facility), prior history of HF, CAD, DM, hypertension, CKD, cerebrovascular disease (CVA), atrial fibrillation, and the use of cardiac devices, the difference in the LOS was not significant between groups (<italic>P</italic> = 0.070).</p>
                </sec>
                <sec id="ehf212448-sec-0024">
                  <title>Safety</title>
                  <p>One patient in the high SpO<sub>2</sub> group was withdrawn after randomization because of high partial pressures of CO<sub>2</sub> and potential risk of hypercapnic failure. Epistaxis related to the use of nasal cannula was reported in one patient in the high SpO<sub>2</sub> arm, but no significant adverse event was reported in any of the two groups.</p>
                </sec>
                <sec id="ehf212448-sec-0025">
                  <title><styled-content style="fixed-case">HiLo‐HF</styled-content> registry</title>
                  <p>Patients in the registry (<italic>n</italic> = 60) had a median age of 77 years, and 35% were women. Thirty‐four (56.7%), 26 (43.3%), and 19 (31.7%) patients had past medical history of HF, CAD, and COPD, respectively. The median time from triage to enrolment was 19.2 (IQR 7.2, 21.5) h, which was longer than that among the trial patients (median 11.4; IQR 7.3, 13.5; <italic>P</italic> &lt; 0.001). Baseline symptoms were similar between registry and trial populations, and there was no difference in terms of VAS AUC, PGA AUC, PEF AUC, and diuretic response (all <italic>P</italic>‐values &gt; 0.05).</p>
                </sec>
                <sec id="ehf212448-sec-0026">
                  <title>Pooled cohort</title>
                  <p>Given that the trial was neutral for primary and secondary endpoints, as the next step, we pooled both trial arms and the <styled-content style="fixed-case">HiLo‐HF</styled-content> registry to form a cohort of 110 patients who presented to ED with AHF.</p>
                  <p>In the first 24 h after randomization, SpO<sub>2</sub> levels were inversely correlated with patients' perception of symptom measured by either dyspnoea VAS or PGA (<italic>r</italic> = −0.36, <italic>P</italic> = 0.014), but there was no correlation after that. At 24 h, patients with SpO<sub>2</sub> &lt; 94% had a higher (i.e. better) dyspnoea VAS (84 vs. 67, <italic>P</italic> = 0.003) and PGA (82 vs. 57, <italic>P</italic> &lt; 0.001) than had those with SpO<sub>2</sub> levels ≥ 94%.</p>
                  <p>Baseline BNP (<italic>n</italic> = 110) or NT‐proBNP (<italic>n</italic> = 50) levels had no correlations with SpO<sub>2</sub> levels, dyspnoea VAS, PGA, or PEF at baseline. There was no correlation between NT‐proBNP levels and SpO<sub>2</sub> levels, dyspnoea VAS, PGA, or PEF at follow‐up (i.e. 72 h) (<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material"><italic>Table</italic> S6</xref>).</p>
                  <p>There was no correlation between ΔSpO<sub>2</sub> and ΔNT‐proBNP from baseline to 72 h in the pilot cohort (<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material"><italic>Figure</italic> S4</xref>). There was no correlation between O<sub>2</sub> administered from baseline to 72 h and the change in NT‐proBNP levels (ΔNT‐proBNP) or the ratio change of NT‐proBNP (Δ/baseline NT‐proBNP) at the same study period (<xref rid="ehf212448-supitem-0001" ref-type="supplementary-material"><italic>Figure</italic> S5</xref>).</p>
                </sec>
              </sec>
            </sec>
            <sec id="ehf212448-sec-0027">
              <title>Discussion</title>
              <p>The <styled-content style="fixed-case">HiLo‐HF</styled-content> pilot trial is the first RCT to explore the effects of supplemental O<sub>2</sub> therapy in patients with AHF. In this trial, titrating O<sub>2</sub> therapy to high or low SpO<sub>2</sub> targets did not result in changes in biomarkers, symptoms, or clinical outcomes. Regardless of group allocation, NT‐proBNP levels, patient‐reported symptoms (e.g. VAS and PGA), and pulmonary function (i.e. PEF) improved over time. In addition, while the pilot demonstrated success in recruitment, the protocol resulted in missing information for a variety of reasons. Overall, these lessons suggest that while a definitive trial is warranted, the protocol and operation of the trial should be further adjusted for pragmatic implementation.</p>
              <p>Three small studies provided the foundation of what we know currently about the possible effects of hyperoxygenation in patients with HF. A study by Mak <italic>et al</italic>. including patients with stable CAD (<italic>n</italic> = 12) and those with HF (<italic>n</italic> = 16) showed that extreme hyperoxia (FiO<sub>2</sub> = 1.0, PaO<sub>2</sub> ~ 300 mmHg) was associated with impairment of cardiac relaxation and increased left ventricular filling pressures in patients with and without HF.<xref rid="ehf212448-bib-0006" ref-type="ref">6</xref> Another study showed that high‐flow O<sub>2</sub> (~5 L/min, FiO<sub>2</sub> ~ 0.40) reduced both cardiac output and heart rate and caused a trend towards increased systemic vascular resistance than did room air (FiO<sub>2</sub> = 0.21).<xref rid="ehf212448-bib-0007" ref-type="ref">7</xref> Finally, the study of Haque <italic>et al</italic>. showed a decrease in stroke volume and an increase in pulmonary capillary wedge pressure with hyperoxia in patients admitted with AHF, and this effect started at an FiO<sub>2</sub> level of 0.24—equivalent to 1 L/min of supplemental O<sub>2</sub>.<xref rid="ehf212448-bib-0005" ref-type="ref">5</xref>
</p>
              <p>The SpO<sub>2</sub> levels in the high SpO<sub>2</sub> arm of this study rose over time with AHF treatment, but these remained steady in the low SpO<sub>2</sub> arm from baseline to 72 h. The manual SpO<sub>2</sub> titration method did not induce a proper separation in SpO<sub>2</sub> levels between the two trial arms. There were some adherence issues, mostly related to the health care professionals' non‐adherence to follow the protocol in down‐titrating O<sub>2</sub> for those with SpO<sub>2</sub> levels above the assigned range. These issues could be partially addressed by utilizing automated closed‐loop systems for controlling supplemental O<sub>2</sub> delivery. These systems provide a potential solution to this problem with near‐constant adjustments and less variability of blood O<sub>2</sub> saturations.<xref rid="ehf212448-bib-0020" ref-type="ref">20</xref> They can regulate the flow of O<sub>2</sub> on a second‐by‐second basis through a sophisticated closed‐loop algorithm that receives data input regarding peripheral O<sub>2</sub> saturation level from pulse oximetry and reacts to that immediately with increasing or decreasing O<sub>2</sub> flow in order to prevent under‐delivery or over‐delivery of O<sub>2</sub>.</p>
              <p>Other studies have attempted to understand the effects associated with supplemental O<sub>2</sub> therapy in other clinical settings.<xref rid="ehf212448-bib-0021" ref-type="ref">21</xref>, <xref rid="ehf212448-bib-0022" ref-type="ref">22</xref>, <xref rid="ehf212448-bib-0023" ref-type="ref">23</xref> A recent meta‐analysis, pooling 7998 patients with acute myocardial infarction from eight RCTs, showed no clinical benefits on mortality or infarct size with supplemental O<sub>2</sub> therapy as compared with room air.<xref rid="ehf212448-bib-0009" ref-type="ref">9</xref> Although the only two small RCTs in patients with cardiac arrest showed no mortality difference between groups treated with high (FiO<sub>2</sub> = 1.0) vs. conservative levels of O<sub>2</sub>,<xref rid="ehf212448-bib-0024" ref-type="ref">24</xref>, <xref rid="ehf212448-bib-0025" ref-type="ref">25</xref> large cohort studies and meta‐analysis of observational studies suggested decreased survival after resuscitation from cardiac arrest with hyperoxia.<xref rid="ehf212448-bib-0026" ref-type="ref">26</xref>, <xref rid="ehf212448-bib-0027" ref-type="ref">27</xref> Studies from the stroke setting demonstrated no benefit of liberal O<sub>2</sub> therapy in those patients.<xref rid="ehf212448-bib-0028" ref-type="ref">28</xref>, <xref rid="ehf212448-bib-0029" ref-type="ref">29</xref> A total of 11 RCTs including 6366 patients with acute stroke showed a non‐significant increase in mortality at 3, 6, and 12 months with normobaric O<sub>2</sub> as compared with room air.<xref rid="ehf212448-bib-0030" ref-type="ref">30</xref> A study in the critical care setting reported an absolute risk reduction of 8.6% for the primary outcome of intensive care unit mortality with conservative O<sub>2</sub> therapy (PaO<sub>2</sub> = 70–100 mmHg or SpO<sub>2</sub> = 94–98%) as compared with usual care (FiO<sub>2</sub> ≥ 0.40, PaO<sub>2</sub> = 100–150 mmHg, and SpO<sub>2</sub> ≥ 97%).<xref rid="ehf212448-bib-0031" ref-type="ref">31</xref> A multi‐centre RCT in patients with stable COPD and moderate desaturation at rest or during exercise showed no benefit of long‐term supplemental O<sub>2</sub> therapy in terms of time to death or hospitalization.<xref rid="ehf212448-bib-0032" ref-type="ref">32</xref> A meta‐analysis of 25 RCTs (16 037 patients) compared the outcomes of liberal vs. conservative O<sub>2</sub> treatment in acutely ill patients and showed liberal oxygenation to increase mortality by roughly 20% in a dose‐dependent way, without improving other patient‐important outcomes such as disability or LOS.<xref rid="ehf212448-bib-0033" ref-type="ref">33</xref>
</p>
              <p>These findings have both clinical and health policy implications. Changes in SpO<sub>2</sub> levels might be a harbinger of patients' deterioration in patients with AHF and hence hyperoxygenation, with masking those changes, decreases the likelihood of timely detection and intervention.<xref rid="ehf212448-bib-0033" ref-type="ref">33</xref> On the other hand, given the cost of O<sub>2</sub> therapy and the ubiquitous use of O<sub>2</sub> in hospitalized or ED patients with AHF,<xref rid="ehf212448-bib-0002" ref-type="ref">2</xref>, <xref rid="ehf212448-bib-0034" ref-type="ref">34</xref> a lack of clinical benefit could mean that by departing from this practice, health care systems could save significant amount of funds from being wasted on a potentially futile intervention and directed towards other treatments with proven efficacies.</p>
              <p>There are several limitations to this study that are noteworthy. The study is a pilot trial, and hence, it is underpowered to detect small differences between study groups. We used a relatively cautious approach of titrating O<sub>2</sub> delivery to a specific saturation. Hence, even patients in the high SpO<sub>2</sub> group did not experience extreme hyperoxia. The use of manual titration method and reliance on the treating team to do that were not associated with proper separation of SpO<sub>2</sub> levels in this study. A device approach using automated closed‐loop systems has the potential to solve that issue. In this study, we did not restrict the patient population to patients with AHF who were normoxaemic at presentation and have included patients with hypoxaemia as well. This will increase the representativeness of our study population to the actual AHF population. However, there is less controversy about the use of O<sub>2</sub> in hypoxaemic patients compared with those with normoxaemia at rest or minimal activity. We lacked data regarding patients' baseline SpO<sub>2,</sub> given that patients were recruited at ED and a proportion of patients had already received O<sub>2</sub> in ambulance or in the ED prior to recruitment. Finally, a change in the timeline for follow‐up NT‐proBNP test from a fixed timeline (72 h) to sampling at 72 h or at discharge if earlier could have prevented a significant proportion of missing data on primary endpoint in this study.</p>
              <p>In conclusion, we found no differences in improvements in NT‐proBNP or patient symptoms between high and low SpO<sub>2</sub> targets in the first 72 h after admission for AHF. Further RCTs with larger sample size are warranted to determine the comparative efficacy and safety of treatment with supplemental O<sub>2</sub> in patients with AHF.</p>
            </sec>
            <sec sec-type="COI-statement" id="ehf212448-sec-0029">
              <title>Conflict of Interest</title>
              <p>None.</p>
            </sec>
            <sec id="ehf212448-sec-0030">
              <title>Funding</title>
              <p>This study was supported by operating grants from the Heart and Stroke Foundation of Canada (HSF) and Alberta Innovates ‐ Health Solutions (AIHS). None of the funding agencies had any input into design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. F.A.M. is supported by the University of Alberta/Capital Health Chair in Cardiovascular Outcomes Research. B.H.R. was supported by a salary award as a Tier I Canada Research Chair in Evidence‐based Emergency Medicine from the Canadian Institutes of Health Research and the Government of Canada (Ottawa, ON). N.S. received a graduate studentship from Alberta Innovates ‐ Health Solutions.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="ehf212448-supitem-0001">
                <caption>
                  <p><bold>Appendix S1.</bold> Oxygen dose adjustment in the Spo<sub>2</sub> titration arms of study.</p>
                  <p><bold>Table S1.</bold> Eligibility criteria for HiLo‐HF RCT and registry.</p>
                  <p><bold>Table S2.</bold> Guideline recommendations regarding oxygen therapy in hypoxemic and normoxemic patients with heart failure.</p>
                  <p><bold>Table S3.</bold> Baseline medications in the study populations of HiLo‐HF trial and registry.</p>
                  <p><bold>Table S4.</bold> Total Furosemide dose at home, during the first 72 hours in hospital and on discharge.</p>
                  <p><bold>Figure S1.</bold> SpO<sub>2</sub> levels and O<sub>2</sub> volumes in two study groups in different study timepoints.</p>
                  <p><bold>Figure S2.</bold> Comparison of the distribution of length of hospital stay (in days &amp; log‐scale) between the intervention groups.</p>
                  <p><bold>Figure S3.</bold> Kaplan–Meier curves of clinical events consisted of in‐hospital mortality and 30‐day death/re‐hospitalization.</p>
                  <p><bold>Table S5.</bold> Patient characteristics in the HiLo patients with available NT‐proBNP data for primary endpoint (<italic>n</italic> = 36).</p>
                  <p><bold>Table S6.</bold> Correlation between natriuretic peptide levels and patient's saturation level and symptoms at baseline and follow‐up.</p>
                  <p><bold>Figure S4.</bold> The relationship between ΔSpO<sub>2</sub> and ΔNT‐BNP in HiLo‐HF cohort (<italic>n</italic> = 50).</p>
                  <p><bold>Figure S5.</bold> The relationship between O<sub>2</sub> from baseline to 72 hours and ΔNT‐BNP in HiLo‐HF cohort (<italic>n</italic> = 50).</p>
                </caption>
                <media xlink:href="EHF2-6-667-s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ehf212448-sec-0028">
              <title>Acknowledgements</title>
              <p>We would like to thank all the participants, the Emergency Medicine Research Group (EMeRG) in the Department of Emergency Medicine at the University of Alberta for their assistance with patient screening; project leads Nubia Zepeda and Melisa Spaling; Quentin Kushnerik; and Dr. Paul M. Brown for his assistance with statistical analysis.</p>
            </ack>
            <ref-list id="ehf212448-bibl-0001" content-type="cited-references">
              <title>References</title>
              <ref id="ehf212448-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0002"><string-name><surname>Yancy</surname><given-names>CW</given-names></string-name>, <string-name><surname>Jessup</surname><given-names>M</given-names></string-name>, <string-name><surname>Bozkurt</surname><given-names>B</given-names></string-name>, <string-name><surname>Butler</surname><given-names>J</given-names></string-name>, <string-name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Drazner</surname><given-names>MH</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Geraci</surname><given-names>SA</given-names></string-name>, <string-name><surname>Horwich</surname><given-names>T</given-names></string-name>, <string-name><surname>Januzzi</surname><given-names>JL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>MR</given-names></string-name>, <string-name><surname>Kasper</surname><given-names>EK</given-names></string-name>, <string-name><surname>Levy</surname><given-names>WC</given-names></string-name>, <string-name><surname>Masoudi</surname><given-names>FA</given-names></string-name>, <string-name><surname>McBride</surname><given-names>PE</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJV</given-names></string-name>, <string-name><surname>Mitchell</surname><given-names>JE</given-names></string-name>, <string-name><surname>Peterson</surname><given-names>PN</given-names></string-name>, <string-name><surname>Riegel</surname><given-names>B</given-names></string-name>, <string-name><surname>Sam</surname><given-names>F</given-names></string-name>, <string-name><surname>Stevenson</surname><given-names>LW</given-names></string-name>, <string-name><surname>Tang</surname><given-names>WHW</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Wilkoff</surname><given-names>BL</given-names></string-name>. <article-title>2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title>. <source xml:lang="en">J Am Coll Cardiol</source><year>2013</year>; <volume>62</volume>: <fpage>e147</fpage>–<lpage>e239</lpage>.<pub-id pub-id-type="pmid">23747642</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0003"><string-name><surname>Ezekowitz</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AF</given-names></string-name>, <string-name><surname>O'Connor</surname><given-names>CM</given-names></string-name>, <string-name><surname>Starling</surname><given-names>RC</given-names></string-name>, <string-name><surname>Proulx</surname><given-names>G</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>MH</given-names></string-name>, <string-name><surname>Bakal</surname><given-names>JA</given-names></string-name>, <string-name><surname>Califf</surname><given-names>RM</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJV</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>PW</given-names></string-name>. <article-title>Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND‐HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow</article-title>. <source xml:lang="en">J Am Coll Cardiol</source><year>2012</year>; <volume>59</volume>: <fpage>1441</fpage>–<lpage>1448</lpage>.<pub-id pub-id-type="pmid">22497823</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0004"><string-name><surname>Sepehrvand</surname><given-names>N</given-names></string-name>, <string-name><surname>Ezekowitz</surname><given-names>JA</given-names></string-name>. <article-title>Oxygen therapy in patients with acute heart failure friend or foe?</article-title><source xml:lang="en">Jacc‐Heart Failure</source><year>2016</year>; <volume>4</volume>: <fpage>783</fpage>–<lpage>790</lpage>.<pub-id pub-id-type="pmid">27289409</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0005"><string-name><surname>Farquhar</surname><given-names>H</given-names></string-name>, <string-name><surname>Weatherall</surname><given-names>M</given-names></string-name>, <string-name><surname>Wijesinghe</surname><given-names>M</given-names></string-name>, <string-name><surname>Perrin</surname><given-names>K</given-names></string-name>, <string-name><surname>Ranchord</surname><given-names>A</given-names></string-name>, <string-name><surname>Simmonds</surname><given-names>M</given-names></string-name>, <string-name><surname>Beasley</surname><given-names>R</given-names></string-name>. <article-title>Systematic review of studies of the effect of hyperoxia on coronary blood flow</article-title>. <source xml:lang="en">Am Heart J</source><year>2009</year>; <volume>158</volume>: <fpage>371</fpage>–<lpage>377</lpage>.<pub-id pub-id-type="pmid">19699859</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0006"><string-name><surname>Haque</surname><given-names>WA</given-names></string-name>, <string-name><surname>Boehmer</surname><given-names>J</given-names></string-name>, <string-name><surname>Clemson</surname><given-names>BS</given-names></string-name>, <string-name><surname>Leuenberger</surname><given-names>UA</given-names></string-name>, <string-name><surname>Silber</surname><given-names>DH</given-names></string-name>, <string-name><surname>Sinoway</surname><given-names>LI</given-names></string-name>. <article-title>Hemodynamic effects of supplemental oxygen administration in congestive heart failure</article-title>. <source xml:lang="en">J Am Coll Cardiol</source><year>1996</year>; <volume>27</volume>: <fpage>353</fpage>–<lpage>357</lpage>.<pub-id pub-id-type="pmid">8557905</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0007"><string-name><surname>Mak</surname><given-names>S</given-names></string-name>, <string-name><surname>Azevedo</surname><given-names>ER</given-names></string-name>, <string-name><surname>Liu</surname><given-names>PP</given-names></string-name>, <string-name><surname>Newton</surname><given-names>GE</given-names></string-name>. <article-title>Effect of hyperoxia on left ventricular function and filling pressures in patients with and without congestive heart failure</article-title>. <source xml:lang="en">Chest</source><year>2001</year>; <volume>120</volume>: <fpage>467</fpage>–<lpage>473</lpage>.<pub-id pub-id-type="pmid">11502645</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0008"><string-name><surname>Park</surname><given-names>JH</given-names></string-name>, <string-name><surname>Balmain</surname><given-names>S</given-names></string-name>, <string-name><surname>Berry</surname><given-names>C</given-names></string-name>, <string-name><surname>Morton</surname><given-names>JJ</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJ</given-names></string-name>. <article-title>Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction</article-title>. <source xml:lang="en">Heart</source><year>2010</year>; <volume>96</volume>: <fpage>533</fpage>–<lpage>538</lpage>.<pub-id pub-id-type="pmid">20350990</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0009"><string-name><surname>Hofmann</surname><given-names>R</given-names></string-name>, <string-name><surname>James</surname><given-names>SK</given-names></string-name>, <string-name><surname>Jernberg</surname><given-names>T</given-names></string-name>, <string-name><surname>Lindahl</surname><given-names>B</given-names></string-name>, <string-name><surname>Erlinge</surname><given-names>D</given-names></string-name>, <string-name><surname>Witt</surname><given-names>N</given-names></string-name>, <string-name><surname>Arefalk</surname><given-names>G</given-names></string-name>, <string-name><surname>Frick</surname><given-names>M</given-names></string-name>, <string-name><surname>Alfredsson</surname><given-names>J</given-names></string-name>, <string-name><surname>Nilsson</surname><given-names>L</given-names></string-name>, <string-name><surname>Ravn‐Fischer</surname><given-names>A</given-names></string-name>, <string-name><surname>Omerovic</surname><given-names>E</given-names></string-name>, <string-name><surname>Kellerth</surname><given-names>T</given-names></string-name>, <string-name><surname>Sparv</surname><given-names>D</given-names></string-name>, <string-name><surname>Ekelund</surname><given-names>U</given-names></string-name>, <string-name><surname>Linder</surname><given-names>R</given-names></string-name>, <string-name><surname>Ekström</surname><given-names>M</given-names></string-name>, <string-name><surname>Lauermann</surname><given-names>J</given-names></string-name>, <string-name><surname>Haaga</surname><given-names>U</given-names></string-name>, <string-name><surname>Pernow</surname><given-names>J</given-names></string-name>, <string-name><surname>Östlund</surname><given-names>O</given-names></string-name>, <string-name><surname>Herlitz</surname><given-names>J</given-names></string-name>, <string-name><surname>Svensson</surname><given-names>L</given-names></string-name>, 
<collab collab-type="authors">DETO2X–SWEDEHEART Investigators</collab>
. <article-title>Oxygen therapy in suspected acute myocardial infarction</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2017</year>; <volume>377</volume>: <fpage>1240</fpage>–<lpage>1249</lpage>.<pub-id pub-id-type="pmid">28844200</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0010"><string-name><surname>Sepehrvand</surname><given-names>N</given-names></string-name>, <string-name><surname>James</surname><given-names>SK</given-names></string-name>, <string-name><surname>Stub</surname><given-names>D</given-names></string-name>, <string-name><surname>Khoshnood</surname><given-names>A</given-names></string-name>, <string-name><surname>Ezekowitz</surname><given-names>JA</given-names></string-name>, <string-name><surname>Hofmann</surname><given-names>R</given-names></string-name>. <article-title>Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta‐analysis of randomised clinical trials</article-title>. <source xml:lang="en">Heart</source><year>2018</year>; <volume>104</volume>: <fpage>1691</fpage>–<lpage>1698</lpage>.<pub-id pub-id-type="pmid">29599378</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0011"><string-name><surname>Stub</surname><given-names>D</given-names></string-name>, <string-name><surname>Smith</surname><given-names>K</given-names></string-name>, <string-name><surname>Bernard</surname><given-names>S</given-names></string-name>, <string-name><surname>Nehme</surname><given-names>Z</given-names></string-name>, <string-name><surname>Stephenson</surname><given-names>M</given-names></string-name>, <string-name><surname>Bray</surname><given-names>JE</given-names></string-name>, <string-name><surname>Cameron</surname><given-names>P</given-names></string-name>, <string-name><surname>Barger</surname><given-names>B</given-names></string-name>, <string-name><surname>Ellims</surname><given-names>AH</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Meredith</surname><given-names>IT</given-names></string-name>, <string-name><surname>Kaye</surname><given-names>DM</given-names></string-name>, 
<collab collab-type="authors">AVOID Investigators</collab>
. <article-title>Air versus oxygen in ST‐segment‐elevation myocardial infarction</article-title>. <source xml:lang="en">Circulation</source>
<year>2015</year>; <volume>131</volume>: <fpage>2143</fpage>–<lpage>2150</lpage>.<pub-id pub-id-type="pmid">26002889</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0012"><string-name><surname>Ezekowitz</surname><given-names>JA</given-names></string-name>, <string-name><surname>O'Meara</surname><given-names>E</given-names></string-name>, <string-name><surname>McDonald</surname><given-names>MA</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>H</given-names></string-name>, <string-name><surname>Chan</surname><given-names>M</given-names></string-name>, <string-name><surname>Ducharme</surname><given-names>A</given-names></string-name>, <string-name><surname>Giannetti</surname><given-names>N</given-names></string-name>, <string-name><surname>Grzeslo</surname><given-names>A</given-names></string-name>, <string-name><surname>Hamilton</surname><given-names>PG</given-names></string-name>, <string-name><surname>Heckman</surname><given-names>GA</given-names></string-name>, <string-name><surname>Howlett</surname><given-names>JG</given-names></string-name>. <article-title>2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure</article-title>. <source xml:lang="en">Can J Cardiol</source><year>2017</year>; <volume>33</volume>: <fpage>1342</fpage>–<lpage>1433</lpage>.<pub-id pub-id-type="pmid">29111106</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0013"><string-name><surname>Lindenfeld</surname><given-names>J</given-names></string-name>, <string-name><surname>Albert</surname><given-names>NM</given-names></string-name>, <string-name><surname>Boehmer</surname><given-names>JP</given-names></string-name>, <string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, <string-name><surname>Ezekowitz</surname><given-names>JA</given-names></string-name>, <string-name><surname>Givertz</surname><given-names>MM</given-names></string-name>, <string-name><surname>Katz</surname><given-names>SD</given-names></string-name>, <string-name><surname>Klapholz</surname><given-names>M</given-names></string-name>, <string-name><surname>Moser</surname><given-names>DK</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>JG</given-names></string-name>, <string-name><surname>Starling</surname><given-names>RC</given-names></string-name>. <article-title>HFSA 2010 comprehensive heart failure practice guideline</article-title>. <source xml:lang="en">J Card Fail</source><year>2010</year>; <volume>16</volume>: <fpage>e1</fpage>–<lpage>e194</lpage>.<pub-id pub-id-type="pmid">20610207</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0014"><string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Voors</surname><given-names>AA</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name><surname>Bueno</surname><given-names>H</given-names></string-name>, <string-name><surname>Cleland</surname><given-names>JG</given-names></string-name>, <string-name><surname>Coats</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Falk</surname><given-names>V</given-names></string-name>, <string-name><surname>González‐Juanatey</surname><given-names>JR</given-names></string-name>, <string-name><surname>Harjola</surname><given-names>VP</given-names></string-name>, <string-name><surname>Jankowska</surname><given-names>EA</given-names></string-name>, <string-name><surname>Jessup</surname><given-names>M</given-names></string-name>. <article-title>2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</article-title>. <source xml:lang="en">Eur J Heart Fail</source><year>2016</year>; <volume>18</volume>: <fpage>891</fpage>–<lpage>975</lpage>.<pub-id pub-id-type="pmid">27207191</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0015"><string-name><surname>Harris</surname><given-names>PA</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>R</given-names></string-name>, <string-name><surname>Thielke</surname><given-names>R</given-names></string-name>, <string-name><surname>Payne</surname><given-names>J</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>N</given-names></string-name>, <string-name><surname>Conde</surname><given-names>JG</given-names></string-name>. <article-title>Research electronic data capture (REDCap)—a metadata‐driven methodology and workflow process for providing translational research informatics support</article-title>. <source xml:lang="en">J Biomed Inform</source><year>2009</year>; <volume>42</volume>: <fpage>377</fpage>–<lpage>381</lpage>.<pub-id pub-id-type="pmid">18929686</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0016"><string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>AA</given-names></string-name>, <string-name><surname>Anker</surname><given-names>SD</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>PW</given-names></string-name>, <string-name><surname>Calvo</surname><given-names>G</given-names></string-name>, <string-name><surname>Cleland</surname><given-names>JGF</given-names></string-name>, <string-name><surname>Cohn</surname><given-names>JN</given-names></string-name>, <string-name><surname>Dickstein</surname><given-names>K</given-names></string-name>, <string-name><surname>Domanski</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ekman</surname><given-names>I</given-names></string-name>, <string-name><surname>Filippatos</surname><given-names>GS</given-names></string-name>, <string-name><surname>Gheorghiade</surname><given-names>M</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AF</given-names></string-name>, <string-name><surname>Jaarsma</surname><given-names>T</given-names></string-name>, <string-name><surname>Koglin</surname><given-names>J</given-names></string-name>, <string-name><surname>Konstam</surname><given-names>M</given-names></string-name>, <string-name><surname>Kupfer</surname><given-names>S</given-names></string-name>, <string-name><surname>Maggioni</surname><given-names>AP</given-names></string-name>, <string-name><surname>Mebazaa</surname><given-names>A</given-names></string-name>, <string-name><surname>Metra</surname><given-names>M</given-names></string-name>, <string-name><surname>Nowack</surname><given-names>C</given-names></string-name>, <string-name><surname>Pieske</surname><given-names>B</given-names></string-name>, <string-name><surname>Piña</surname><given-names>IL</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Rosano</surname><given-names>G</given-names></string-name>, <string-name><surname>Ruilope</surname><given-names>LM</given-names></string-name>, <string-name><surname>Ruschitzka</surname><given-names>F</given-names></string-name>, <string-name><surname>Severin</surname><given-names>T</given-names></string-name>, <string-name><surname>Solomon</surname><given-names>S</given-names></string-name>, <string-name><surname>Stein</surname><given-names>K</given-names></string-name>, <string-name><surname>Stockbridge</surname><given-names>NL</given-names></string-name>, <string-name><surname>Stough</surname><given-names>WG</given-names></string-name>, <string-name><surname>Swedberg</surname><given-names>K</given-names></string-name>, <string-name><surname>Tavazzi</surname><given-names>L</given-names></string-name>, <string-name><surname>Voors</surname><given-names>AA</given-names></string-name>, <string-name><surname>Wasserman</surname><given-names>SM</given-names></string-name>, <string-name><surname>Woehrle</surname><given-names>H</given-names></string-name>, <string-name><surname>Zalewski</surname><given-names>A</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>JJV</given-names></string-name>. <article-title>Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document</article-title>. <source xml:lang="en">Eur J Heart Fail</source><year>2013</year>; <volume>15</volume>: <fpage>1082</fpage>–<lpage>1094</lpage>.<pub-id pub-id-type="pmid">23787718</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0017"><string-name><surname>Felker</surname><given-names>GM</given-names></string-name>, <string-name><surname>Pang</surname><given-names>PS</given-names></string-name>, <string-name><surname>Adams</surname><given-names>KF</given-names></string-name>, <string-name><surname>Cleland</surname><given-names>JG</given-names></string-name>, <string-name><surname>Cotter</surname><given-names>G</given-names></string-name>, <string-name><surname>Dickstein</surname><given-names>K</given-names></string-name>, <string-name><surname>Filippatos</surname><given-names>GS</given-names></string-name>, <string-name><surname>Fonarow</surname><given-names>GC</given-names></string-name>, <string-name><surname>Greenberg</surname><given-names>BH</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AF</given-names></string-name>, <string-name><surname>Khan</surname><given-names>S</given-names></string-name>, <string-name><surname>Komajda</surname><given-names>M</given-names></string-name>, <string-name><surname>Konstam</surname><given-names>MA</given-names></string-name>, <string-name><surname>Liu</surname><given-names>PP</given-names></string-name>, <string-name><surname>Maggioni</surname><given-names>AP</given-names></string-name>, <string-name><surname>Massie</surname><given-names>BM</given-names></string-name>, <string-name><surname>McMurray</surname><given-names>J</given-names></string-name>, <string-name><surname>Mehra</surname><given-names>M</given-names></string-name>, <string-name><surname>Metra</surname><given-names>M</given-names></string-name>, <string-name><surname>O'Connell</surname><given-names>J</given-names></string-name>, <string-name><surname>O'Connor</surname><given-names>CM</given-names></string-name>, <string-name><surname>Pina</surname><given-names>IL</given-names></string-name>, <string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Sabbah</surname><given-names>HN</given-names></string-name>, <string-name><surname>Teerlink</surname><given-names>JR</given-names></string-name>, <string-name><surname>Udelson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Yancy</surname><given-names>CW</given-names></string-name>, <string-name><surname>Zannad</surname><given-names>F</given-names></string-name>, <string-name><surname>Gheorghiade</surname><given-names>M</given-names></string-name>, 
<collab collab-type="authors">International AHFS Working Group</collab>
. <article-title>Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward</article-title>. <source xml:lang="en">Circ Heart Fail</source>
<year>2010</year>; <volume>3</volume>: <fpage>314</fpage>–<lpage>325</lpage>.<pub-id pub-id-type="pmid">20233993</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0018"><string-name><surname>Teerlink</surname><given-names>JR</given-names></string-name>, <string-name><surname>Cotter</surname><given-names>G</given-names></string-name>, <string-name><surname>Davison</surname><given-names>BA</given-names></string-name>, <string-name><surname>Felker</surname><given-names>GM</given-names></string-name>, <string-name><surname>Filippatos</surname><given-names>G</given-names></string-name>, <string-name><surname>Greenberg</surname><given-names>BH</given-names></string-name>, <string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Unemori</surname><given-names>E</given-names></string-name>, <string-name><surname>Voors</surname><given-names>AA</given-names></string-name>, <string-name><surname>Adams</surname><given-names>KF</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Dorobantu</surname><given-names>MI</given-names></string-name>, <string-name><surname>Grinfeld</surname><given-names>LR</given-names></string-name>, <string-name><surname>Jondeau</surname><given-names>G</given-names></string-name>, <string-name><surname>Marmor</surname><given-names>A</given-names></string-name>, <string-name><surname>Masip</surname><given-names>J</given-names></string-name>, <string-name><surname>Pang</surname><given-names>PS</given-names></string-name>, <string-name><surname>Werdan</surname><given-names>K</given-names></string-name>, <string-name><surname>Teichman</surname><given-names>SL</given-names></string-name>, <string-name><surname>Trapani</surname><given-names>A</given-names></string-name>, <string-name><surname>Bush</surname><given-names>CA</given-names></string-name>, <string-name><surname>Saini</surname><given-names>R</given-names></string-name>, <string-name><surname>Schumacher</surname><given-names>C</given-names></string-name>, <string-name><surname>Severin</surname><given-names>TM</given-names></string-name>, <string-name><surname>Metra</surname><given-names>M</given-names></string-name>. <article-title>Serelaxin, recombinant human relaxin‐2, for treatment of acute heart failure (RELAX‐AHF): a randomised, placebo‐controlled trial</article-title>. <source xml:lang="en">Lancet</source><year>2013</year>; <volume>381</volume>: <fpage>29</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">23141816</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0019"><string-name><surname>Felker</surname><given-names>GM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>KL</given-names></string-name>, <string-name><surname>Bull</surname><given-names>DA</given-names></string-name>, <string-name><surname>Redfield</surname><given-names>MM</given-names></string-name>, <string-name><surname>Stevenson</surname><given-names>LW</given-names></string-name>, <string-name><surname>Goldsmith</surname><given-names>SR</given-names></string-name>, <string-name><surname>LeWinter</surname><given-names>M</given-names></string-name>, <string-name><surname>Deswal</surname><given-names>A</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>JL</given-names></string-name>, <string-name><surname>Ofili</surname><given-names>EO</given-names></string-name>, <string-name><surname>Anstrom</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Hernandez</surname><given-names>AF</given-names></string-name>, <string-name><surname>McNulty</surname><given-names>S</given-names></string-name>, <string-name><surname>Velazquez</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Kfoury</surname><given-names>AG</given-names></string-name>, <string-name><surname>Chen</surname><given-names>HH</given-names></string-name>, <string-name><surname>Givertz</surname><given-names>MM</given-names></string-name>, <string-name><surname>Semigran</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Bart</surname><given-names>BA</given-names></string-name>, <string-name><surname>Mascette</surname><given-names>AM</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name><surname>O'Connor</surname><given-names>CM</given-names></string-name>, 
<collab collab-type="authors">NHLBI Heart Failure Clinical Research Network</collab>
. <article-title>Diuretic strategies in patients with acute decompensated heart failure</article-title>. <source xml:lang="en">N Engl J Med</source>
<year>2011</year>; <volume>364</volume>: <fpage>797</fpage>–<lpage>805</lpage>.<pub-id pub-id-type="pmid">21366472</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0020"><string-name><surname>Voors</surname><given-names>AA</given-names></string-name>, <string-name><surname>Davison</surname><given-names>BA</given-names></string-name>, <string-name><surname>Teerlink</surname><given-names>JR</given-names></string-name>, <string-name><surname>Felker</surname><given-names>GM</given-names></string-name>, <string-name><surname>Cotter</surname><given-names>G</given-names></string-name>, <string-name><surname>Filippatos</surname><given-names>G</given-names></string-name>, <string-name><surname>Greenberg</surname><given-names>BH</given-names></string-name>, <string-name><surname>Pang</surname><given-names>PS</given-names></string-name>, <string-name><surname>Levin</surname><given-names>B</given-names></string-name>, <string-name><surname>Hua</surname><given-names>TA</given-names></string-name>, <string-name><surname>Severin</surname><given-names>T</given-names></string-name>, <string-name><surname>Ponikowski</surname><given-names>P</given-names></string-name>, <string-name><surname>Metra</surname><given-names>M</given-names></string-name>, 
<collab collab-type="authors">for the RELAX‐AHF Investigators</collab>
. <article-title>Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome—an analysis from RELAX‐AHF</article-title>. <source xml:lang="en">Eur J Heart Fail</source>
<year>2014</year>; <volume>16</volume>: <fpage>1230</fpage>–<lpage>1240</lpage>.<pub-id pub-id-type="pmid">25287144</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0021"><string-name><surname>Lellouche</surname><given-names>F</given-names></string-name>, <string-name><surname>L'Her</surname><given-names>E</given-names></string-name>. <article-title>Automated oxygen flow titration to maintain constant oxygenation</article-title>. <source xml:lang="en">Respir Care</source><year>2012</year>; <volume>57</volume>: <fpage>1254</fpage>–<lpage>1262</lpage>.<pub-id pub-id-type="pmid">22348812</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0022"><string-name><surname>Clark</surname><given-names>AL</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>M</given-names></string-name>, <string-name><surname>Fairhurst</surname><given-names>C</given-names></string-name>, <string-name><surname>Torgerson</surname><given-names>D</given-names></string-name>, <string-name><surname>Cockayne</surname><given-names>S</given-names></string-name>, <string-name><surname>Rodgers</surname><given-names>S</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>S</given-names></string-name>, <string-name><surname>Allgar</surname><given-names>V</given-names></string-name>, <string-name><surname>Jones</surname><given-names>L</given-names></string-name>, <string-name><surname>Nabb</surname><given-names>S</given-names></string-name>, <string-name><surname>Harvey</surname><given-names>I</given-names></string-name>. <article-title>Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure</article-title>. <source xml:lang="en">Health Technol Assess</source><year>2015</year>; <volume>19</volume>: <fpage>1</fpage>–<lpage>120</lpage>.</mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0023"><string-name><surname>Koshy</surname><given-names>A</given-names></string-name>, <string-name><surname>Pellicori</surname><given-names>P</given-names></string-name>, <string-name><surname>Clark</surname><given-names>AL</given-names></string-name>. <article-title>The effect of increasing inspired oxygen on exercise performance in patients with chronic heart failure</article-title>. <source xml:lang="en">Heart</source><year>2016</year>; <volume>102</volume>: <fpage>597</fpage>–<lpage>601</lpage>.<pub-id pub-id-type="pmid">26891754</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0024"><string-name><surname>Shah</surname><given-names>P</given-names></string-name>, <string-name><surname>Pellicori</surname><given-names>P</given-names></string-name>, <string-name><surname>Rimmer</surname><given-names>S</given-names></string-name>, <string-name><surname>Rigby</surname><given-names>AS</given-names></string-name>, <string-name><surname>Clark</surname><given-names>AL</given-names></string-name>. <article-title>Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction</article-title>. <source xml:lang="en">Int J Cardiol</source><year>2018</year>; <volume>268</volume>: <fpage>166</fpage>–<lpage>169</lpage>.<pub-id pub-id-type="pmid">29803343</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0025"><string-name><surname>Young</surname><given-names>P</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>M</given-names></string-name>, <string-name><surname>Bellomo</surname><given-names>R</given-names></string-name>, <string-name><surname>Bernard</surname><given-names>S</given-names></string-name>, <string-name><surname>Dicker</surname><given-names>B</given-names></string-name>, <string-name><surname>Freebairn</surname><given-names>R</given-names></string-name>, <string-name><surname>Henderson</surname><given-names>S</given-names></string-name>, <string-name><surname>Mackle</surname><given-names>D</given-names></string-name>, <string-name><surname>McArthur</surname><given-names>C</given-names></string-name>, <string-name><surname>McGuinness</surname><given-names>S</given-names></string-name>, <string-name><surname>Smith</surname><given-names>T</given-names></string-name>, <string-name><surname>Swain</surname><given-names>A</given-names></string-name>, <string-name><surname>Weatherall</surname><given-names>M</given-names></string-name>, <string-name><surname>Beasley</surname><given-names>R</given-names></string-name>. <article-title>HyperOxic Therapy OR NormOxic Therapy after out‐of‐hospital cardiac arrest (HOT OR NOT): a randomised controlled feasibility trial</article-title>. <source xml:lang="en">Resuscitation</source><year>2014</year>; <volume>85</volume>: <fpage>1686</fpage>–<lpage>1691</lpage>.<pub-id pub-id-type="pmid">25261605</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0026"><string-name><surname>Kuisma</surname><given-names>M</given-names></string-name>, <string-name><surname>Boyd</surname><given-names>J</given-names></string-name>, <string-name><surname>Voipio</surname><given-names>V</given-names></string-name>, <string-name><surname>Alaspaa</surname><given-names>A</given-names></string-name>, <string-name><surname>Roine</surname><given-names>RO</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>P</given-names></string-name>. <article-title>Comparison of 30 and the 100% inspired oxygen concentrations during early post‐resuscitation period: a randomised controlled pilot study</article-title>. <source xml:lang="en">Resuscitation</source><year>2006</year>; <volume>69</volume>: <fpage>199</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">16500018</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0027"><string-name><surname>Damiani</surname><given-names>E</given-names></string-name>, <string-name><surname>Adrario</surname><given-names>E</given-names></string-name>, <string-name><surname>Girardis</surname><given-names>M</given-names></string-name>, <string-name><surname>Romano</surname><given-names>R</given-names></string-name>, <string-name><surname>Pelaia</surname><given-names>P</given-names></string-name>, <string-name><surname>Singer</surname><given-names>M</given-names></string-name>, <string-name><surname>Donati</surname><given-names>A</given-names></string-name>. <article-title>Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Crit Care</source><year>2014</year>; <volume>18</volume>: <fpage>711</fpage>.<pub-id pub-id-type="pmid">25532567</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0028"><string-name><surname>Helmerhorst</surname><given-names>HJF</given-names></string-name>, <string-name><surname>Roos‐Blom</surname><given-names>M‐J</given-names></string-name>, <string-name><surname>van Westerloo</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Abu‐Hanna</surname><given-names>A</given-names></string-name>, <string-name><surname>de Keizer</surname><given-names>NF</given-names></string-name>, <string-name><surname>de Jonge</surname><given-names>E</given-names></string-name>. <article-title>Associations of arterial carbon dioxide and arterial oxygen concentrations with hospital mortality after resuscitation from cardiac arrest</article-title>. <source xml:lang="en">Crit Care</source><year>2015</year>; <volume>19</volume>: <fpage>348</fpage>.<pub-id pub-id-type="pmid">26415731</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0029"><string-name><surname>Ali</surname><given-names>K</given-names></string-name>, <string-name><surname>Warusevitane</surname><given-names>A</given-names></string-name>, <string-name><surname>Lally</surname><given-names>F</given-names></string-name>, <string-name><surname>Sim</surname><given-names>J</given-names></string-name>, <string-name><surname>Sills</surname><given-names>S</given-names></string-name>, <string-name><surname>Pountain</surname><given-names>S</given-names></string-name>, <string-name><surname>Nevatte</surname><given-names>T</given-names></string-name>, <string-name><surname>Allen</surname><given-names>M</given-names></string-name>, <string-name><surname>Roffe</surname><given-names>C</given-names></string-name>. <article-title>The stroke oxygen pilot study: a randomized controlled trial of the effects of routine oxygen supplementation early after acute stroke—effect on key outcomes at six months</article-title>. <source xml:lang="en">PLoS ONE</source><year>2014</year>; <volume>8</volume>: <fpage>e59274</fpage>.<pub-id pub-id-type="pmid">23755093</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0030"><string-name><surname>Pountain</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Roffe</surname><given-names>C</given-names></string-name>. <article-title>Does routine oxygen supplementation in patients with acute stroke improve outcome?</article-title><source xml:lang="en">BMJ</source><year>2012</year>; <volume>345</volume>: <fpage>e6976</fpage>.<pub-id pub-id-type="pmid">23204040</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0031"><string-name><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>D</given-names></string-name>. <article-title>The effect of normobaric oxygen in patients with acute stroke: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Neurol Res</source><year>2018</year>; <volume>40</volume>: <fpage>433</fpage>–<lpage>444</lpage>.<pub-id pub-id-type="pmid">29600891</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0032"><string-name><surname>Girardis</surname><given-names>M</given-names></string-name>, <string-name><surname>Busani</surname><given-names>S</given-names></string-name>, <string-name><surname>Damiani</surname><given-names>E</given-names></string-name>, <string-name><surname>Donati</surname><given-names>A</given-names></string-name>, <string-name><surname>Rinaldi</surname><given-names>L</given-names></string-name>, <string-name><surname>Marudi</surname><given-names>A</given-names></string-name>, <string-name><surname>Morelli</surname><given-names>A</given-names></string-name>, <string-name><surname>Antonelli</surname><given-names>M</given-names></string-name>, <string-name><surname>Singer</surname><given-names>M</given-names></string-name>. <article-title>Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen‐ICU Randomized Clinical Trial</article-title>. <source xml:lang="en">JAMA</source><year>2016</year>; <volume>316</volume>: <fpage>1583</fpage>–<lpage>1589</lpage>.<pub-id pub-id-type="pmid">27706466</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0033"><string-name><surname>Albert</surname><given-names>RK</given-names></string-name>, <string-name><surname>Au</surname><given-names>DH</given-names></string-name>, <string-name><surname>Blackford</surname><given-names>AL</given-names></string-name>, <string-name><surname>Casaburi</surname><given-names>R</given-names></string-name>, <string-name><surname>Cooper</surname><given-names>JA</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Criner</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>P</given-names></string-name>, <string-name><surname>Fuhlbrigge</surname><given-names>AL</given-names></string-name>, <string-name><surname>Gay</surname><given-names>SE</given-names></string-name>, <string-name><surname>Kanner</surname><given-names>RE</given-names></string-name>, <string-name><surname>MacIntyre</surname><given-names>N</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>FJ</given-names></string-name>, <string-name><surname>Panos</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Piantadosi</surname><given-names>S</given-names></string-name>, <string-name><surname>Sciurba</surname><given-names>F</given-names></string-name>, <string-name><surname>Shade</surname><given-names>D</given-names></string-name>, <string-name><surname>Stibolt</surname><given-names>T</given-names></string-name>, <string-name><surname>Stoller</surname><given-names>JK</given-names></string-name>, <string-name><surname>Wise</surname><given-names>R</given-names></string-name>, <string-name><surname>Yusen</surname><given-names>RD</given-names></string-name>, <string-name><surname>Tonascia</surname><given-names>J</given-names></string-name>, <string-name><surname>Sternberg</surname><given-names>AL</given-names></string-name>, <string-name><surname>Bailey</surname><given-names>W</given-names></string-name>. <article-title>A randomized trial of long‐term oxygen for COPD with moderate desaturation</article-title>. <source xml:lang="en">N Engl J Med</source><year>2016</year>; <volume>375</volume>: <fpage>1617</fpage>–<lpage>1627</lpage>.<pub-id pub-id-type="pmid">27783918</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0034"><string-name><surname>Chu</surname><given-names>DK</given-names></string-name>, <string-name><surname>Kim</surname><given-names>LH</given-names></string-name>, <string-name><surname>Young</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Zamiri</surname><given-names>N</given-names></string-name>, <string-name><surname>Almenawer</surname><given-names>SA</given-names></string-name>, <string-name><surname>Jaeschke</surname><given-names>R</given-names></string-name>, <string-name><surname>Szczeklik</surname><given-names>W</given-names></string-name>, <string-name><surname>Schünemann</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Neary</surname><given-names>JD</given-names></string-name>, <string-name><surname>Alhazzani</surname><given-names>W</given-names></string-name>. <article-title>Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Lancet</source><year>2018</year>; <volume>391</volume>: <fpage>1693</fpage>–<lpage>1705</lpage>.<pub-id pub-id-type="pmid">29726345</pub-id></mixed-citation>
              </ref>
              <ref id="ehf212448-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="ehf212448-cit-0035"><string-name><surname>Siemieniuk</surname><given-names>RAC</given-names></string-name>, <string-name><surname>Chu</surname><given-names>DK</given-names></string-name>, <string-name><surname>Kim</surname><given-names>LH</given-names></string-name>, <string-name><surname>Güell‐Rous</surname><given-names>MR</given-names></string-name>, <string-name><surname>Alhazzani</surname><given-names>W</given-names></string-name>, <string-name><surname>Soccal</surname><given-names>PM</given-names></string-name>, <string-name><surname>Karanicolas</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Farhoumand</surname><given-names>PD</given-names></string-name>, <string-name><surname>Siemieniuk</surname><given-names>JL</given-names></string-name>, <string-name><surname>Satia</surname><given-names>I</given-names></string-name>, <string-name><surname>Irusen</surname><given-names>EM</given-names></string-name>. <article-title>Oxygen therapy for acutely ill medical patients: a clinical practice guideline</article-title>. <source xml:lang="en">BMJ</source><year>2018</year>; <volume>363</volume>: <elocation-id>k4169</elocation-id>.<pub-id pub-id-type="pmid">30355567</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
